4 results
1) To identify T2 low biomarkers and 2) to unravel the mechanisms and downstream effects of Tezepelumab in T2 low asthma.
The aim of this global Phase III study is to investigate the use of tezepelumab as a treatment for patients with EoE. This study will evaluate the efficacy and safety of tezepelumab 210 mg every 4 weeks (Q4W) and tezepelumab 420mg Q4W administered…
To evaluate the effect of tezepelumab as compared with placebo on COPD exacerbations in subjects with moderate to very severe COPD
Primary objectives:Safety for Dose Selection• To assess the safety and tolerability of PQ912Efficacy • To evaluate the efficacy of PQ912 on working memory and attentionSecondary Objectives:Safety• To assess the safety and tolerability of long-term…